GRFS
Grifols SAPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 404M | Q1 2026 call | — |
| Adjusted EBITDA (reported) non-GAAP | 381M | Q1 2026 call | — |
| Albumin sales growth | -6.1% | Q1 2026 call | — |
| Alpha 1 & Specialty proteins sales growth | -7.4% | Q1 2026 call | — |
| Biopharma growth | 6.8% | Q1 2026 call | — |
| Free cash flow improvement non-GAAP | 30M | Q1 2026 call | — |
| Immunoglobulins (IG) portfolio growth | 15.3% | Q1 2026 call | — |
| Leverage non-GAAP | 4.3 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRFS
this stock
Grifols SA
|
$4.95B | -22.2% | — | — | 2.4% |
|
LLY
ELI LILLY & Co
|
$1.12T | +10.8% | +44.7% | 42.2 | 1.0% |
|
JNJ
Johnson & Johnson
|
$618.61B | +24.8% | +6.0% | 29.8 | 1.1% |
|
ABBV
AbbVie Inc.
|
$438.31B | +9.4% | +8.6% | 122.2 | 1.2% |
|
MRK
Merck & Co., Inc.
|
$305.12B | +19.1% | +1.4% | 34.8 | 1.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRFS | +1.5% | -0.9% | -18.6% | +2.7% | -22.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +0.2% | -5.0% | -27.7% | +1.6% | -33.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.